Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma

被引:0
|
作者
Sug Hyung Lee
Min Sun Shin
Hong Sug Kim
Hun Kyung Lee
Won Sang Park
Su Young Kim
Jong Heun Lee
Seo Young Han
Jik Young Park
Ro Ra Oh
Chang Suk Kang
Kyung Mee Kim
Ja June Jang
Suk Woo Nam
Jung Young Lee
Nam Jin Yoo
机构
[1] College of Medicine,Department of Pathology
[2] The Catholic University of Korea,Department of Clinical Pathology
[3] College of Medicine,Department of Pathology and Cancer Research Center
[4] The Catholic University of Korea,undefined
[5] Seoul National University College of Medicine,undefined
[6] Laboratory of Pathology,undefined
[7] National Cancer Institute,undefined
[8] NIH,undefined
来源
Oncogene | 2001年 / 20卷
关键词
mutation; TRAIL-receptor 1; TRAIL-receptor 2; non-Hodgkin's lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
Tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. TRAIL-R1 and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL). Because TRAIL/TRAIL receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-R1 and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL. In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-R1 gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-R1 gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-R1 and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-R1 and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R1 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL.
引用
收藏
页码:399 / 403
页数:4
相关论文
共 50 条
  • [1] Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma
    Lee, SH
    Shin, MS
    Kim, HS
    Lee, HK
    Park, WS
    Kim, SY
    Lee, JH
    Han, SY
    Park, JY
    Oh, RR
    Kang, CS
    Kim, KM
    Jang, JJ
    Nam, SW
    Lee, JY
    Yoo, NJ
    [J]. ONCOGENE, 2001, 20 (03) : 399 - 403
  • [2] Translating TRAIL-receptor targeting agents to the clinic
    den Hollander, Martha W.
    Gietema, Jourik A.
    de Jong, Steven
    Walenkamp, Annemiek M. E.
    Reyners, Anna K. L.
    Oldenhuis, Corina N. A. M.
    de Vries, Elisabeth G. E.
    [J]. CANCER LETTERS, 2013, 332 (02) : 194 - 201
  • [3] TRAIL-receptor 2 protein expression in normal and tumor tissues
    Halpern, Wendy
    Lincoln, Clint
    Roach, Charlotte
    Sharifi, Amir
    Askaa, Jon
    Welcher, Rosanne
    Klein-Szanto, Andres
    Cohen, Roger
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 22 - 23
  • [4] Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease
    Brost, Sylvia
    Koschny, Ronald
    Sykora, Jaromir
    Stremmel, Wolfgang
    Lasitschka, Felix
    Walczak, Henning
    Ganten, Tom M.
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2010, 206 (01) : 43 - 50
  • [5] TRAIL-receptor 2—a novel negative regulator of p53
    Anna Willms
    Hella Schupp
    Michelle Poelker
    Alshaimaa Adawy
    Jan Frederik Debus
    Torsten Hartwig
    Tim Krichel
    Jürgen Fritsch
    Steven Singh
    Henning Walczak
    Silvia von Karstedt
    Heiner Schäfer
    Anna Trauzold
    [J]. Cell Death & Disease, 12
  • [6] Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
    Krishna Moorthy, Nivetha
    Seifert, Oliver
    Eisler, Stephan
    Weirich, Sara
    Kontermann, Roland E.
    Rehm, Markus
    Fullstone, Gavin
    [J]. MOLECULES, 2021, 26 (24):
  • [7] Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System
    Sarhan, Dhifaf
    D'Arcy, Padraig
    Lundqvist, Andreas
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (10) : 18557 - 18573
  • [8] TRAIL (APO2L) and TRAIL-receptor expression in relation to survival of patients with glioblastoma multiforme
    Kuijlen, JMA
    Mooij, JJA
    Hollema, H
    Hoving, EW
    van der Graaf, WTA
    den Dunnen, WFA
    [J]. NEURO-ONCOLOGY, 2005, 7 (03) : 371 - 371
  • [9] A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
    Kobayashi, Eiji
    Kishi, Hiroyuki
    Ozawa, Tatsuhiko
    Hamana, Hiroshi
    Nakagawa, Hidetoshi
    Jin, Aishun
    Li, Zhezhu
    Muraguchi, Atsushi
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 453 (04) : 798 - 803
  • [10] TRAIL-receptor 2-a novel negative regulator of p53
    Willms, Anna
    Schupp, Hella
    Poelker, Michelle
    Adawy, Alshaimaa
    Debus, Jan Frederik
    Hartwig, Torsten
    Krichel, Tim
    Fritsch, Juergen
    Singh, Steven
    Walczak, Henning
    von Karstedt, Silvia
    Schaefer, Heiner
    Trauzold, Anna
    [J]. CELL DEATH & DISEASE, 2021, 12 (08)